FDA Approves Updated Aduhelm Prescribing Information to Emphasize Population Studied in Clinical Trials

Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd....
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials